Get started
Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028

Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028

No trades
See on Supercharts
OverviewChartAnalysisNews

US2043QAC1 chart



Key terms


Outstanding amount
‪661.25 M‬ USD
Face value
1,000.00 USD
Minimum denomination
1,000.00 USD
Coupon
0% (Zero)
Coupon frequency
—
Yield to maturity
—
Maturity date
Sep 15, 2028
Term to maturity
2 years

About Alnylam Pharmaceuticals, Inc. 0.0% 15-SEP-2028


Issuer
Alnylam Pharmaceuticals, Inc.
Sector
Health Technology
Industry
Pharmaceuticals: Major
Home page
alnylam.com
Issue date
Sep 12, 2025
ISIN
US02043QAC15
FIGI
BBG01X5VX1N8
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

See how Alnylam Pharmaceuticals, Inc. is moving with its highest-yielding bonds.

US2043QAC1 analysis


Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.

US2043QAC1 news